Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pasithea Therapeutics (KTTA) Depreciation & Amortization (CF) (2022 - 2024)

Pasithea Therapeutics (KTTA) has disclosed Depreciation & Amortization (CF) for 3 consecutive years, with $4852.0 as the latest value for Q4 2024.

  • Quarterly Depreciation & Amortization (CF) rose 3.68% to $4852.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $19569.0 through Dec 2024, up 6.99% year-over-year, with the annual reading at $49000.0 for FY2025, 157.89% up from the prior year.
  • Depreciation & Amortization (CF) hit $4852.0 in Q4 2024 for Pasithea Therapeutics, down from $5000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $16670.0 in Q3 2022 to a low of $4138.0 in Q4 2022.
  • Historically, Depreciation & Amortization (CF) has averaged $6205.7 across 3 years, with a median of $4784.5 in 2024.
  • Biggest YoY gain for Depreciation & Amortization (CF) was 13.1% in 2023; the steepest drop was 71.72% in 2023.
  • Year by year, Depreciation & Amortization (CF) stood at $4138.0 in 2022, then rose by 13.1% to $4680.0 in 2023, then increased by 3.68% to $4852.0 in 2024.
  • Business Quant data shows Depreciation & Amortization (CF) for KTTA at $4852.0 in Q4 2024, $5000.0 in Q3 2024, and $5000.0 in Q2 2024.